Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Rapcabtagene autoleucel

Cell therapy (CAR-T) · Kills target cells, directed at CD19 · developed by Novartis Pharmaceuticals

Phase 1/2 Most advanced trial
NVS Developer

What is Rapcabtagene autoleucel?

Rapcabtagene autoleucel is a cell therapy of autologous T cells engineered to express a chimeric antigen receptor.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (CAR-T)
Targets
CD19 (antigen)
Mechanism
Kills target cells, directed at CD19
Therapy area
Oncology
Developer
Novartis Pharmaceuticals (NVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

Conditions studied

Acute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaDiffuse Large B-cell LymphomaLarge B-cell LymphomaSmall Lymphocytic Lymphoma

Other drugs acting on CD19

More from Novartis Pharmaceuticals

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Rapcabtagene autoleucel

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.